SCHEMBL4476763

SCHEMBL4476763

CN(CCN1CCC(OC(=O)N(c2ccccc2-c2ccccc2)N(C(=O)O)c2ccccc2-c2ccccc2)CC1)C(=O)c1cccc(C(=O)NCCN(Cc2ncc[nH]2)Cc2ncc[nH]2)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
HTR7 P34969 2/20 0.36
HTR1A P08908 1/20 0.36
FYN P06241 2/20 0.36
CHRM3 P20309 2/20 0.35
ADRB2 P07550 1/20 0.35
CARM1 Q86X55 3/20 0.35
PRMT6 Q96LA8 2/20 0.35
PRMT8 Q9NR22 1/20 0.35
SLC5A7 Q9GZV3 1/20 0.35
SMYD2 Q9NRG4 1/20 0.34
EPHX2 P34913 1/20 0.34
DRD2 P14416 1/20 0.34
NAMPT P43490 2/20 0.34
PRKD1 Q15139 1/20 0.33
CAMK2D Q13557 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490144 0.91 CHRM2 (0.39) CHRM2HTR7HTR1AFYNCHRM3
SCHEMBL266026 0.87 CHRM2 (0.54) CHRM2CHRM3ADRB2
SCHEMBL4479676 0.85 CARM1 (0.45) CHRM2HTR7HTR1ACHRM3ADRB2
SCHEMBL4490830 0.84 CHRM2 (0.44) CHRM2HTR7HTR1ACHRM3ADRB2
SCHEMBL4475841 0.84 CHRM2 (0.43) CHRM2HTR7HTR1ACHRM3ADRB2
SCHEMBL4476769 0.83 HTR7 (0.37) HTR7HTR1AFYNCHRM3ADRB2
SCHEMBL4491995 0.81 CHRM2 (0.41) CHRM2HTR7HTR1ACHRM3ADRB2
SCHEMBL4483079 0.81 CHRM3 (0.44) CHRM2HTR7HTR1ACHRM3ADRB2
SCHEMBL4472532 0.80 CHRM2 (0.41) CHRM2HTR7HTR1ACHRM3ADRB2
SCHEMBL4480089 0.80 CHRM2 (0.43) CHRM2HTR7HTR1ACHRM3ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed